You are here: Industry Insights > NSCLC

News List

CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC prnasia
September 13, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines...
Libtayo® with chemotherapy trial stopped early due to success europeanpharmaceuticalreview
August 10, 2021
Phase III trial of Libtayo® (cemiplimab) combined with chemotherapy stops early due to significant improvement in overall survival in lung cancer patients.
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement pharmatimes
August 09, 2021
A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in combination with platinum-doublet chemotherapy has been stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small cell ...
US FDA grants priority review to Roche’s Tecentriq as adjuvant treatment for non-small cell lung cancer expresspharma
August 04, 2021
Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting.
Nuvalent Announces Closing of Upsized Initial Public Offering firstwordpharma
August 03, 2021
Nuvalent, Inc. today announced the closing of its upsized initial public offering of 11,212,500 shares of common stock, consisting of 10,612,500 shares of Class A common stock and 600,000 shares of Class B common stock
Merck’s MET inhibitor tepotinib gains positive opinion from MHRA pharmatimes
July 16, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued a positive scientific opinion for Merck’s tepotinib for the treatment of advanced non-small cell lung cancer (NSCLC) with METex14 skipping alterations.
Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
July 02, 2021
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the closing of an underwritten public offering of 3,565,000 shares of its common stock at a public offering price of $48.50 per share.
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock firstwordpharma
June 29, 2021
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the commencement of a proposed underwritten public offering of $150 million of shares of its common stock.
CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication appl prnasia
June 24, 2021
CStone Pharmaceuticals today announced data from the China registrational study of the global pivotal Phase 1/2 ARROW trial.
Arcus says early data for anti-TIGIT domvanalimab combos look good, but mum on details firstwordpharma
June 24, 2021
Arcus Biosciences on Wednesday said a Phase II study testing combinations of its anti-TIGIT monoclonal antibody domvanalimab (AB154), which is partnered with Gilead Sciences, showed "encouraging" results when given as first-line treatment .

Previous page 1 2 3 4 5 6 7 8 9 10 ... 20 21 Next page